Results 61 to 70 of about 1,486 (188)

S4.5c Using serum beta-glucan measurements and sequencing of the Madurella mycetomatis azole target gene to predict therapeutic outcome during azole treatment in human mycetoma

open access: yesMedical Mycology, 2022
S4.5 Mycetoma Clinical Trial on fosravuconazole treatment in eumycetoma– Top Line Results, September 22, 2022, 10:30 AM - 12:00 PM Objectives Eumycetoma is a neglected tropical disease characterized by large subcutaneous swellings and the formation of ...
B. Nyuykonge   +8 more
semanticscholar   +1 more source

A Madurella mycetomatis Grain Model in Galleria mellonella Larvae. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2015
Eumycetoma is a chronic granulomatous subcutaneous infectious disease, endemic in tropical and subtropical regions and most commonly caused by the fungus Madurella mycetomatis.
Wendy Kloezen   +3 more
doaj   +1 more source

Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi

open access: yesAdvanced Science, Volume 12, Issue 37, October 6, 2025.
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda   +12 more
wiley   +1 more source

The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma

open access: yesPLoS Neglected Tropical Diseases, 2021
Mycetoma is a devastating neglected tropical infection of the subcutaneous tissue and most commonly caused by the fungus Madurella mycetomatis. Treatment of mycetoma consists of a combination of a long term antifungal treatment with itraconazole and ...
Mickey Konings   +6 more
semanticscholar   +1 more source

A Rare Presentation of Concurrent Scedosporium apiospermum and Madurella grisea Eumycetoma in an Immunocompetent Host

open access: yesCase Reports in Pathology, 2012
Mycetoma is a disfiguring, chronic granulomatous infection which affects the skin and the underlying subcutaneous tissue. We present an atypical case of recurrent mycetoma without ulceration, in a 35-year-old immunocompetent male caused by Scedosporium ...
Vivek Gulati   +5 more
doaj   +1 more source

Plant‐Based Mycetoma Inhibitors Targeting the 50S Ribosomal Protein of Nocardia brasiliensis: In Silico Approach

open access: yesChemistrySelect, Volume 10, Issue 21, June 4, 2025.
In‐silico drug discovery pipeline for Mycetoma caused by Nocardia brasiliensis. A library of 1034 phytocompounds was screened to identify potent inhibitors, with Parviflorone F showing strong binding and stability against the 50S ribosomal unit. Molecular dynamics confirmed its inhibitory potential, offering a promising therapeutic candidate.
Sandra Jose   +7 more
wiley   +1 more source

Madurella grisea: a case report on an uncommon cause for mycetoma

open access: yesSri Lankan Journal of Infectious Diseases, 2017
Madura foot is a disfiguring, disabling condition, found in the tropics and subtropics. We present a case of a farmer who presented with swelling and multiple discharging sinuses in his left foot.
M. N. Jayawardena   +2 more
doaj   +1 more source

Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2021–2022

open access: yesMass Spectrometry Reviews, Volume 44, Issue 3, Page 213-453, May/June 2025.
Abstract The use of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this review is the 12th update of the original article published in 1999 and brings coverage of the literature to the end of 2022.
David J. Harvey
wiley   +1 more source

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

open access: yesChemical Biology &Drug Design, Volume 105, Issue 1, January 2025.
The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley   +1 more source

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim

open access: yesJournal of Antimicrobial Chemotherapy, 2020
Objectives Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the ...
W. Lim   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy